---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-25-000050"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:08:08.595104+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical reports record Q4 revenue $8.9M (+23% YoY); positive cash flow in Q4

## Summary
- Preliminary full-year 2024 net revenue of $33.7M, up 18% YoY; Q4 revenue $8.9M, up 23% YoY.
- Ending cash balance $9.6M; Q4 generated positive cash flow of $0.8M.
- Full-year cash burn $1.9M, a 67% improvement over prior year.
- CEO cites U.S. market share gains, international expansion, and progress on new drug therapy labeling.

## SEC filing metadata
- accession: 0001161697-25-000050
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169725000050/0001161697-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169725000050/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-25-000050
- JSON: https://secwatch.observer/filing/0001161697-25-000050.json
- Plain text: https://secwatch.observer/filing/0001161697-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.